Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011040735> ?p ?o ?g. }
- W2011040735 endingPage "272" @default.
- W2011040735 startingPage "257" @default.
- W2011040735 abstract "Circulating antinuclear autoantibodies (ANAs) are well known to accompany various pathological conditions and can be artificially induced by immunization. Research and clinical data permit us to hypothesize a definite connection between cancer and ANAs. Based on the available data, my group’s research suggested that exogenous ANAs may be used as anticancer therapeutics. Among these ANAs, nucleosome-specific ANAs may be particularly useful. Advances in cancer immunotherapy with monoclonal antibodies re-emphasized the role of humoral immunity in neoplasia control. The development of a universal antibody targeting diverse cancers is of clear importance. We showed that certain natural ANAs recognize the surface of numerous tumor cells but not normal cells via cell surface-bound nucleosomes originating from the apoptotically dying neighboring tumor cells, mediate antibody-dependent cellular cytotoxicity of tumor cells in vitro and inhibit the development of murine tumor in syngeneic mice. A single monoclonal antinuclear nucleosome-specific autoantibody, mAb 2C5, specifically recognizes multiple unrelated human tumor cell lines and accumulates at a high tumor-to-normal cell ratio in various human tumors in nude mice. Immunotherapy with mAb 2C5 resulted in significant suppression of the growth of several human tumors. In addition, mAb 2C5, when used in subtherapeutic quantities, can serve as a highly efficient specific ligand to target various drug- or diagnostic agent-loaded pharmaceutical nanocarriers, such as liposomes and polymeric micelles, to various tumors. Here, the data (accumulated predominantly in our laboratory over several years) on mAb 2C5-mediated tumor targeting of chemotherapeutic agents is reviewed." @default.
- W2011040735 created "2016-06-24" @default.
- W2011040735 creator A5084391530 @default.
- W2011040735 date "2010-08-01" @default.
- W2011040735 modified "2023-10-18" @default.
- W2011040735 title "Antinuclear antibodies with nucleosome-restricted specificity for targeted delivery of chemotherapeutic agents" @default.
- W2011040735 cites W1507548252 @default.
- W2011040735 cites W1507651754 @default.
- W2011040735 cites W1537863230 @default.
- W2011040735 cites W1554543161 @default.
- W2011040735 cites W1585414631 @default.
- W2011040735 cites W1597614503 @default.
- W2011040735 cites W1599584901 @default.
- W2011040735 cites W160911776 @default.
- W2011040735 cites W1628836607 @default.
- W2011040735 cites W16537224 @default.
- W2011040735 cites W1899643807 @default.
- W2011040735 cites W1917754692 @default.
- W2011040735 cites W1963670762 @default.
- W2011040735 cites W1969402650 @default.
- W2011040735 cites W1970229342 @default.
- W2011040735 cites W1970855558 @default.
- W2011040735 cites W1971796295 @default.
- W2011040735 cites W1972703248 @default.
- W2011040735 cites W1973727813 @default.
- W2011040735 cites W1974850600 @default.
- W2011040735 cites W1981455261 @default.
- W2011040735 cites W1983363336 @default.
- W2011040735 cites W1983671192 @default.
- W2011040735 cites W1987125650 @default.
- W2011040735 cites W1995147666 @default.
- W2011040735 cites W1995637639 @default.
- W2011040735 cites W1995995697 @default.
- W2011040735 cites W1997797597 @default.
- W2011040735 cites W1998136765 @default.
- W2011040735 cites W1998634984 @default.
- W2011040735 cites W1999220393 @default.
- W2011040735 cites W2002516695 @default.
- W2011040735 cites W2004305723 @default.
- W2011040735 cites W2006290379 @default.
- W2011040735 cites W2008290615 @default.
- W2011040735 cites W2008950719 @default.
- W2011040735 cites W2010697977 @default.
- W2011040735 cites W2011571744 @default.
- W2011040735 cites W2011732682 @default.
- W2011040735 cites W2015164514 @default.
- W2011040735 cites W2015943384 @default.
- W2011040735 cites W2016156919 @default.
- W2011040735 cites W2019144805 @default.
- W2011040735 cites W2020532274 @default.
- W2011040735 cites W2021233105 @default.
- W2011040735 cites W2025412364 @default.
- W2011040735 cites W2025919388 @default.
- W2011040735 cites W2025987074 @default.
- W2011040735 cites W2026128884 @default.
- W2011040735 cites W2026359053 @default.
- W2011040735 cites W2030063736 @default.
- W2011040735 cites W2030905355 @default.
- W2011040735 cites W2032437474 @default.
- W2011040735 cites W2032903640 @default.
- W2011040735 cites W2034690275 @default.
- W2011040735 cites W2042175907 @default.
- W2011040735 cites W2043371238 @default.
- W2011040735 cites W2046422929 @default.
- W2011040735 cites W2048827359 @default.
- W2011040735 cites W2050049641 @default.
- W2011040735 cites W2055951605 @default.
- W2011040735 cites W2056252055 @default.
- W2011040735 cites W2056347214 @default.
- W2011040735 cites W2058360844 @default.
- W2011040735 cites W2059002761 @default.
- W2011040735 cites W2059700588 @default.
- W2011040735 cites W2061510929 @default.
- W2011040735 cites W2061643328 @default.
- W2011040735 cites W2066987196 @default.
- W2011040735 cites W2068508373 @default.
- W2011040735 cites W2071152014 @default.
- W2011040735 cites W2071532342 @default.
- W2011040735 cites W2072718490 @default.
- W2011040735 cites W2074694034 @default.
- W2011040735 cites W2075209490 @default.
- W2011040735 cites W2075278421 @default.
- W2011040735 cites W2076328260 @default.
- W2011040735 cites W2076687046 @default.
- W2011040735 cites W2076941870 @default.
- W2011040735 cites W2078816993 @default.
- W2011040735 cites W2081501602 @default.
- W2011040735 cites W2085163546 @default.
- W2011040735 cites W2086537209 @default.
- W2011040735 cites W2087597184 @default.
- W2011040735 cites W2091141889 @default.
- W2011040735 cites W2092652665 @default.
- W2011040735 cites W2092706112 @default.
- W2011040735 cites W2093846994 @default.
- W2011040735 cites W2098927273 @default.
- W2011040735 cites W2099513954 @default.
- W2011040735 cites W2100202254 @default.
- W2011040735 cites W2104197204 @default.